Evaluation of the Predictive Impact of Serum S100B and S100B Polymorphisms on Postoperative Cognitive Dysfunction and Delirium
Key facts
- Who runs it
- Ankara University
- Where
- Türkiye1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 137 people enrolled
- Started
- 27 Sept 2023
- Ended
- 6 Nov 2024
- Type of study
- Observational
- Treatments tested
- Perioperative Assessment
- Record updated
- 3 April 2026
Who can take part
- Age
- 18 years to 120 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Adult patients (≥18 years) undergoing elective surgery under anesthesia
- Patients able to provide informed consent
- Patients with sufficient cognitive function to complete cognitive assessments
- Patients who agreed to participate in follow-up evaluations
Who cannot take part
- Patients undergoing emergency surgery
- Patients with a history of neurological or psychiatric disorders affecting cognitive function
- Patients with diagnosed dementia or severe cognitive impairment
- Patients with inability to complete cognitive tests (e.g., severe visual, hearing, or language impairment)
- Patients with alcohol or substance abuse
- Patients with missing baseline cognitive assessment
- Patients who refused participation or were lost to follow-up
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Postoperative cognitive disorders, including postoperative cognitive dysfunction (POCD) and postoperative delirium (POD), are common complications following surgery and anesthesia, particularly in vulnerable patient populations. These conditions are associated with increased morbidity, prolonged hospitalization, and higher healthcare costs. Early identification of patients at risk remains challenging, and reliable biomarkers are needed to improve perioperative risk stratification.
Read full original descriptionShow less
S100B protein has been proposed as a biomarker of neuronal injury and blood-brain barrier dysfunction. In addition, genetic variations in the S100B gene may influence individual susceptibility to postoperative cognitive impairment.
The aim of this prospective cohort study is to evaluate the association between perioperative serum S100B levels, S100B gene polymorphisms, and postoperative cognitive disorders. Furthermore, the predictive value of perioperative changes in S100B levels for postoperative cognitive dysfunction and delirium will be investigated.
The group in the trial
- Surgical Patients
Patients undergoing surgery who were prospectively followed for postoperative delirium and postoperative cognitive dysfunction with serial cognitive assessments, serum S100B measurements, and S100B gene polymorphism analyses.
Treatment: Perioperative Assessment
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Investigation of the Predictive Effect of Serum S100B and S100B Polymorphisms on Postoperative Cognitive Dysfunction and Delirium in Patients Undergoing Surgery With Bispectral Index Monitoring
- Record updated
- 3 April 2026